GLUT1: Difference between revisions

Fasentin is a small molecule inhibitor of the intracellular domain of GLUT1 preventing glucose uptake.<ref name="pmid19001437">{{cite journal | vauthors = Wood TE, Dalili S, Simpson CD, Hurren R, Mao X, Saiz FS, Gronda M, Eberhard Y, Minden MD, Bilan PJ, Klip A, Batey RA, Schimmer AD | title = A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death | journal = Molecular Cancer Therapeutics | volume = 7 | issue = 11 | pages = 3546–55 | date = November 2008 | pmid = 19001437 | doi = 10.1158/1535-7163.MCT-08-0569 | url = http://mct.aacrjournals.org/cgi/pmidlookup?view=long&pmid=19001437 }}</ref>.

Recently, a new more selective GLUT1 inhibitor, Bay-876, has been described. <ref name="pmid27552707">{{cite journal |vauthors=Siebeneicher H, Cleve A, Rehwinkel H, Neuhaus R, Heisler I, Müller T, Bauser M, Buchmann B |title=Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876 |journal=ChemMedChem |volume=7 |issue=11 |pages=3546–55 |date=October 2016 |pmid=27552707 |doi=10.1002/cmdc.201600276 |doi-access=free}}</ref>.